WAVE Life Sciences (WVE)
(Real Time Quote from BATS)
$4.80 USD
+0.06 (1.27%)
Updated Apr 26, 2024 01:24 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Wave Life Sciences (WVE) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$13.00 | $19.00 | $5.00 | 174.26% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Wave Life Sciences comes to $13.00. The forecasts range from a low of $5.00 to a high of $19.00. The average price target represents an increase of 174.26% from the last closing price of $4.74.
Analyst Price Targets (6 )
Broker Rating
Wave Life Sciences currently has an average brokerage recommendation (ABR) of 1.50 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 1.50 a month ago based on six recommendations.
Of the six recommendations deriving the current ABR, four are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 66.67% and 16.67% of all recommendations. A month ago, Strong Buy made up 66.67%, while Buy represented 16.67%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 4 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 1 | 1 | 1 | 1 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.50 | 1.50 | 1.50 | 1.50 | 1.71 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/1/2024 | Truist Securities | Joon Lee | Strong Buy | Strong Buy |
3/12/2024 | Mizuho SecuritiesUSA | Salim Syed | Strong Buy | Strong Buy |
3/7/2024 | H.C. Wainwright & Co. | Andrew S Fein | Strong Buy | Strong Buy |
12/19/2023 | SVB Securities | Joseph P Schwartz | Hold | Strong Buy |
11/9/2023 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.50 |
ABR (Last week) | 1.50 |
# of Recs in ABR | 6 |
Average Target Price | $13.00 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 75 of 252 |
Current Quarter EPS Est: | -0.18 |